Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 86.5%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a significant decline in short interest in August. As of August 14th, there was short interest totaling 187 shares, a decline of 86.5% from the July 30th total of 1,385 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 1,011 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on MOLN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Wednesday, July 8th. HC Wainwright reaffirmed a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.38.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Molecular Partners stock. SmartHarvest Portfolios LLC grew its position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) by 26.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,543 shares of the company’s stock after acquiring an additional 3,232 shares during the quarter. SmartHarvest Portfolios LLC’s holdings in Molecular Partners were worth $62,000 at the end of the most recent reporting period. Institutional investors own 26.55% of the company’s stock.

Molecular Partners Price Performance

Shares of NASDAQ MOLN traded up $0.03 during mid-day trading on Wednesday, hitting $4.41. 1,178 shares of the company’s stock traded hands, compared to its average volume of 4,819. The company’s 50-day moving average is $4.04 and its two-hundred day moving average is $4.23. The company has a market capitalization of $178.12 million, a P/E ratio of -2.27 and a beta of 1.08. Molecular Partners has a 1 year low of $3.53 and a 1 year high of $5.36.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Tuesday, August 25th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.02. Equities analysts anticipate that Molecular Partners will post -1.28 EPS for the current fiscal year.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.